References
- Bartel DP : MicroRNAs: genomics, biogenesis, mechanism, and function.Cell116 , 281–297 (2004).
- Flamant S , RitchieW, GuilhotJ et al.: Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemiaHaematologica95(8) , 1325–1333 (2010).
- Venturini L , BattmerK, CastoldiM et al.: Expression of the miR-17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells.Blood109 , 4399–4405 (2007).
- Agirre X , Jimenez-VelascoA, San Jose-Eneriz R et al.: Down regulation of has-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol. Cancer Res.6 , 1830–1840 (2008).
- Lidonnici MR , CorradiniF, WaldronT et al.: Requirement of c-Myb for p210(BCR-ABL)-dependent transformation of hematopoietic progenitors and leukemogenesis.Blood111 , 4771–4779 (2008).
- Eiring AM , HarbJG, NevianiP et al.: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.Cell140 , 652–665 (2010).
References
- Sharma P , KumarL, MohantyS et al.: Response to imatinib mesylate in chronic myeloid leukaemia patients with variant BCR-ABL fusion transcripts.Ann. Haematol.89(3) , 241–247 (2010).
- Lomaia EG , MartinkevichIS, OgorodnikovaYS et al.: b2a2 type BCR-ABL transcript chronic myelogenous leukemia (CML) patients in chronic phase (CP) on Glivec achieve complete cytognetic remission (CCyR) earlier than those with b3a2.Blood108(Suppl.) , 4780 (2006).
- De Lemos JA , De Oliveira CM, Scerni AC et al.: Differential molecular response of the transcripts B2a2 and B3a2 to imatinib mesylate in chronic myeloid leukemia. Genet. Mol. Res.4(4) , 803–811 (2005).
- Polampalli S , ChoughuleA, NegiN et al.: Analysis and comparison of clinic-hematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcriptsGenet. Mol. Res.7(4) , 1138–1149 (2008).
- Vega-Ruiz A , KantarjianH, ShanJ et al.: Better molecular response to imatinib for patients (pts) with chronic myeloid leukemia (CML) in chronic phase (CP) carrying the b3a2 transcript compared with b2a2.Blood110(Suppl.) , 1939 (2007).
- Lucas CM , HarrisRJ, GiannoudisA et al.: Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared with patients with the e14a2 transcript.Haematologica94(10) , 1362–1367 (2009).
References
- Peng B , LloydP, SchranH: Clinical pharmacokinetics of imatinib.Clin. Pharmacokinet.44 , 879–894 (2005).
- Le Coutre P , KreuzerKA, PurscheS et al.: Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.Cancer Chemother. Pharmacol.53 , 313–323 (2004).
- Géen H , SkoglundK, RommelF et al.: CYP3A activity influences imatinib response in patients with chronic myeloid leukaemia: a pilot study on in vivo CYP3A activity.Eur. J. Clin. Pharmacol.66(4) , 383–386 (2010).
- Picard S , TitierK, EtienneG et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.Blood109 , 3496–3499 (2007).